Led · Equity · Mar 2026

MindImmune Therapeutics engineers therapies that target the immune system’s role in neurodegeneration, aiming to curb the neuroinflammatory processes that accelerate diseases like Alzheimer’s. Its research identifies and modulates specific biological pathways responsible for inflammation-driven neuronal damage. The company is advancing a new class of drug candidates designed to meaningfully change the course of neurodegenerative disorders rather than merely treating symptoms. With its latest capital, MindImmune plans to complete critical translational studies and prepare an Investigational New Drug (IND) submission to the FDA. The funding will also underwrite strategic planning for the program’s first clinical trials, bringing its lead candidates closer to human testing. Although revenue figures have not been disclosed, the $5 million infusion strengthens the firm’s financial runway as it moves from preclinical work toward early clinical development.

Participated · Series A · Dec 2025

Circular Genomics is building a proprietary circular RNA (circRNA) biomarker platform that analyzes highly stable, brain-enriched non-coding RNAs from whole blood to detect neurological disease biology before symptoms appear. Its lead application is an Alzheimer’s disease assay designed to outperform current PET and CSF diagnostics by providing an accessible, pathway-level view of neurodegeneration. The company’s data show robust prediction models, identification of presymptomatic patients, and specificity versus other dementias, positioning the test for use in early screening, patient stratification, and longitudinal monitoring. Beyond Alzheimer’s, Circular Genomics plans to expand its platform into other neurodegenerative and psychiatric conditions such as Parkinson’s disease, major depressive disorder, and bipolar disorder. Near-term priorities include completing large clinical validation studies, enhancing the biomarker panel, forming strategic partnerships with pharma and diagnostic providers, and growing the commercial and scientific teams. The recent $15 million Series A financing provides the capital required to advance these initiatives and prepare the first assay for market launch.

Led · Equity · Sep 2024

C2N Diagnostics develops the Precivity portfolio of blood tests and high-resolution LC‑MS/MS biomarker services to aid diagnosis and management of Alzheimer’s disease. Its Precivity tests detect amyloid and tau biomarkers and have been used in over 150 research studies, with more than 30,000 Precivity-related biomarker measures reported. C2N operates a CLIA‑certified, CAP‑accredited laboratory in St. Louis and provides testing as laboratory-developed tests (LDTs), with access via a U.S. network of over 700 patient service centers and 13,000 mobile phlebotomists. The company plans to build a fully automated, standardized, high-resolution LC‑MS clinical analyzer and accompanying diagnostic kits to enable decentralized, local deployment of its assays worldwide. The global scalability project will accommodate multiple assays tracking amyloid and tau pathology and provide a framework to add future neuropathology assays. C2N has established partnerships to expand access to Precivity testing, including a multi-year exclusive agreement with Unilabs for Europe and a non-exclusive agreement with Mayo Clinic Laboratories. The company received an investment of up to $7.025 million from the Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator to support the LC‑MS platform effort. C2N Diagnostics develops and provides high-resolution mass spectrometry-based biomarker services and the Precivity™ blood tests intended for use in patients with cognitive impairment. Its Precivity tests are designed to help healthcare providers determine Alzheimer’s disease pathology and aid medical management and treatment decisions. C2N assays have been used in over 150 Alzheimer’s disease and other research studies worldwide, and over 15,000 Precivity-related biomarker measures have been reported in peer-reviewed publications. The company collaborates with pharmaceutical and biotech companies, leading academic institutions, the National Institute on Aging, the Alzheimer’s Association, and other non-profits and consortiums to support clinical trials and research. With Eisai’s investment, C2N plans to scale up and expand the availability, accessibility, and use of its high-performance blood biomarker tests for early diagnosis of Alzheimer’s disease in the U.S. The company also acknowledges support from the National Institute on Aging, GHR Foundation, Alzheimer’s Drug Discovery Foundation, BrightFocus Foundation, and Alzheimer’s Association. C2N Diagnostics develops and commercializes blood-based biomarkers for Alzheimer’s disease, including the PrecivityAD® test and the next-generation PrecivityAD2™. The company uses high-resolution mass spectrometry to provide laboratory services and products that support clinical decision-making, clinical trials, and research into neurodegeneration. C2N plans to use new capital to advance PrecivityAD2™, run additional clinical studies to build real-world evidence, and expand global market access and medical education. The company will also invest in biomarker pipeline development, infrastructure growth, and workflow efficiencies to prepare for higher testing volumes and commercial demand. C2N recently marked the two-year anniversary of the PrecivityAD® launch and says the test is the first widely accessible blood test to assist healthcare providers with Alzheimer’s diagnosis. The company acknowledges support from funders including the National Institute on Aging, GHR Foundation, Alzheimer’s Drug Discovery Foundation, BrightFocus Foundation, and the Alzheimer’s Association. C2N Diagnostics is commercializing the APTUS™ platform, a panel of blood tests to enable early detection and monitoring of neurodegenerative disorders. Its lead APTUS-Aβ™ test combines mass spectrometry quantification of plasma Aβ42/Aβ40, ApoE status, and age to predict brain amyloidosis. The APTUS-Aβ test received Breakthrough Device Designation from the FDA in early 2019 and is being positioned for clinical use under CLIA. C2N was formed by scientists from Washington University School of Medicine in St. Louis and LifeTech Research and operates a CLIA-certified clinical laboratory facility in St. Louis, Missouri. The company also developed a portfolio of anti-tau antibodies and formed a global partnership with AbbVie in March 2015 to develop and commercialize those assets. With the new funding, C2N plans to establish a premium quality patient testing service, pursue an IVD label with the FDA, and seek reimbursement from CMS while expanding its global growth and diagnostic pipeline.

Participated · Series B · Aug 2024

NeuroTherapia, led by President and CEO Tony Giordano and based in Cleveland, OH, is a clinical-stage biotech developing oral, small-molecule drugs to address neuro-inflammatory CNS conditions including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. Its lead program, NTRX-07, is an orally available cannabinoid receptor agonist intended to inhibit microglia-mediated inflammation without affecting clearance of toxic beta amyloid. The company says its therapeutics aim to inhibit proteins expressed by microglia that drive CNS inflammation while preserving amyloid clearance. NeuroTherapia raised $12.3M in a Series B financing and intends to use the proceeds for continued clinical development of NTRX-07. The company plans a second close in six months to raise additional funds to enable development of a recently discovered second-generation molecule for a separate indication driven by neuroinflammation. No operating metrics (revenue/users) were disclosed in the article. NeuroTherapia is an early-stage clinical pharmaceutical company developing NTRX-07, a first-in-class drug candidate for Alzheimer’s disease. The company announced it has received a grant from the Alzheimer’s Association Part the Cloud program to support development of NTRX-07. NTRX-07 is being developed as a treatment for Alzheimer’s disease. The grant provides funding to advance the program through development. As an early-stage clinical firm, NeuroTherapia's near-term plans center on progressing NTRX-07. The company issued the announcement in a press release from NeuroTherapia, Inc. NeuroTherapia is a Cleveland, OH-based clinical-stage company developing NTRX-07, an orally available cannabinoid receptor agonist aimed at treating neuroinflammation implicated in neurodegenerative diseases. The company is completing its first-in-human clinical trial of NTRX-07, with part of the trial funded by an Alzheimer’s Association grant. It closed an $8.8M Series A to finish the first-in-human work and to undertake additional preclinical studies. The planned preclinical studies are intended to support subsequent clinical trials by demonstrating safety following longer-term administration and showing biological activity. Separately, NeuroTherapia received a $150,000 Technology Validation and Start-up Fund grant from Ohio Third Frontier to complete biodistribution research after radiolabeling the molecule. The company also strengthened its board with the addition of Karoly Nikolich, Ph.D., joining existing board members including the chairman Mr. Reher, President and CEO Tony Giordano, Ph.D., and Akhil Saklecha, M.D., from Cleveland Clinic.

Participated · Series A · Jul 2024

RetiSpec develops AI solutions applied to non-invasive retinal images to identify neurodegenerative disease markers and provide real-time results at the point of care. Its first clinically validated AI is intended to predict amyloid burden to aid evaluation for Alzheimer’s disease. RetiSpec’s solutions are currently available for Research Use Only. The company aims to enable widespread early and accurate detection of neurodegenerative disease through a routine eye exam. Leadership is headed by co-founder and CEO Eliav Shaked. The company is based in Toronto, Canada and has raised $17M USD to date.